Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ADMA vs ELVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADMA Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)

ADMA Overall Winner 6-Pillar Tally: ADMA 6 – 0 ELVN Matrix Metrics: ADMA 6 – 4 ELVN

As of Nov 16, 2026, ADMA Biologics, Inc. (ADMA) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ADMA carries a Unified Composite Score of 23.7/100 (STRONG SELL) at $13.70 (15.7x Forward P/E, 44.9% operating margin), whereas ELVN carries 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ELVN currently prints a higher short-term Unified Composite Score (36.2/100 SELL vs. ADMA 23.7/100 STRONG SELL), ADMA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (44.9% vs. 0.0% operating margin) and revenue trajectory (+5.1% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although ADMA compares more favorably head-to-head, both ADMA (23.7/100 STRONG SELL) and ELVN (36.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADMA vs ELVN
ADMA NASDAQ Head-to-Head Winner
ADMA Biologics, Inc.
Biological Products, (No Disgnostic Substances)
$13.70
+0.11% 1D
Market Cap $2.9B
TTM Revenue $519M
Forward P/E 15.7x
Beta / 30D Vol -0.42β · 99% Vol
Unified Composite Score
23.7 / 100 STRONG SELL
Tech 50.0 Fund 35.0 Flow 66.0 Mom 25.9
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.5% over 20 days), RSI 71
RSI-14: 71.1 · SMA20: $11.92 · SMA50: $10.66
ELVN NASDAQ
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 60% Vol
Unified Composite Score
36.2 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.2 · SMA20: $45.77 · SMA50: $46.19

6-Pillar Scorecard Institutional Category Breakdown (ADMA 6 – 0 ELVN)

Columns: Metric · ADMA · ELVN
1. Valuation Multiples ADMA
Forward P/E 15.7x N/M
Trailing P/E 17.2x N/M
PEG Ratio N/M N/M
EV / Revenue 5.8x N/M
2. Growth & Scale ADMA
Revenue Growth (YoY) +5.1% +0.0%
Earnings Growth (YoY) +46.7% +0.0%
TTM Revenue (USD) $519M N/A
Market Cap $2.9B $3.6B
3. Profitability & Quality ADMA
Gross Margin 68.5% N/A
Operating Margin 44.9% 0.0%
Net Profit Margin 35.1% 0.0%
Return on Equity (ROE) 41.9% -16.8%
4. Balance Sheet & Cash Flow ADMA
Cash Generation (TTM) $133M -$66M
Cash Flow Margin 25.5% N/A
Net Cash / Leverage $78M Net Debt (0.46x D/E) $150M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADMA
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 45.1% (8th %ile) 46.9% (5th %ile)
Put/Call OI Skew 0.08x (Call-Skewed) 1.67x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ADMA
OpEx & R&D Intensity 23.6% of Rev ($123M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADMA (6) vs ELVN (4)
Institutional Metric ADMA ELVN Criterion Row Edge
Market Capitalization
Scale
$2.9B $3.6B Larger Scale ELVN
Trailing P/E Ratio
Valuation
17.2x N/M Lower Multiple ADMA
Forward P/E Ratio
Valuation
15.7x N/M Lower Multiple ADMA
Revenue Growth (YoY)
Growth
+5.1% +0.0% Higher Growth ADMA
Operating Margin (TTM)
Profitability
44.9% 0.0% Higher Margin ADMA
Net Profit Margin
Profitability
35.1% 0.0% Higher Margin ADMA
Return on Equity (ROE)
Capital Efficiency
41.9% -16.8% Higher ROE ADMA
52-Week Range Position
Momentum
49% ($7–$20) 69% ($15–$62) Stronger Trend ELVN
Beta / 30D Volatility
Risk Regime
-0.42β · 99% Vol 0.96β · 60% Vol Lower Realized Risk ELVN
Unified Institutional Score
Composite Signal
23.7 / 100 (STRONG SELL) 36.2 / 100 (SELL) Higher Composite ELVN
Trailing 12M Revenue (USD)
Operating Scale
$519M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$133M ($78M Net Debt (0.46x D/E)) -$66M ($150M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADMA +0.85 pp
ADMA: +28.23% · ELVN: +27.38%
3M Horizon ADMA +64.41 pp
ADMA: +43.55% · ELVN: -20.86%
6M Horizon ADMA +43.46 pp
ADMA: +63.42% · ELVN: +19.96%
1Y Horizon ELVN +147.3 pp
ADMA: -12.77% · ELVN: +134.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADMA vs ELVN. Trailing 12-month operating profitability (ADMA 44.9% vs ELVN 0.0%) and valuation multiples (ADMA 15.7x vs ELVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ADMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$519M
Gross Margin68.5%
Op. Margin44.9%
ROE / Fwd P/E41.9% · 15.7x
ELVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-16.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADMA SURGE
7d in phase · OBV ACCUMULATION
Current IV 45.1%
IV Percentile 8th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ELVN CONSOLIDATION
59d in phase · OBV NEUTRAL
Current IV 46.9%
IV Percentile 5th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADMA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and 44.9% operating margin.
OpEx & R&D Reinvestment 23.6% of Rev ($123M)
90D Engineering Disclosures 0 Published
ELVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADMA vs ELVN Key Questions & Quantitative Answers

As of Nov 16, 2026, ADMA Biologics, Inc. (ADMA) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ADMA carries a Unified Composite Score of 23.7/100 (STRONG SELL) at $13.70 (15.7x Forward P/E, 44.9% operating margin), whereas ELVN carries 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ELVN currently prints a higher short-term Unified Composite Score (36.2/100 SELL vs. ADMA 23.7/100 STRONG SELL), ADMA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (44.9% vs. 0.0% operating margin) and revenue trajectory (+5.1% vs. +0.0% YoY). Defensive Composite Rating Caution: Although ADMA compares more favorably head-to-head, both ADMA (23.7/100 STRONG SELL) and ELVN (36.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

ADMA leads the Growth & Scale pillar: ADMA posts +5.1% YoY revenue growth and +46.7% YoY earnings growth on $519M TTM revenue (68.5% gross margin, 44.9% operating margin), compared with ELVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ADMA generates $519M in USD-normalized revenue versus N/A for ELVN. In operating R&D and SG&A reinvestment, ADMA deploys 23.6% of Rev ($123M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ELVN.

ADMA screens cheaper on headline valuation multiples. ADMA trades at 15.7x Forward P/E, 17.2x Trailing P/E, N/M PEG, and 5.8x EV/Revenue (25.5% FCF margin), whereas ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADMA (41.9% ROE) versus ELVN (-16.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ADMA carries 45.1% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (-0.42β · 99% Vol realized risk). By comparison, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.